The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Fentora is a great, but potentially dangerous product. With it's significant narcotic effect, it should only be prescirbed to appropriate patients by those with experience. The recent deaths were likely due to poor patient selection and lack of experience by the providers.
Diabetes continues to be a global problem with hefty costs in dollars, death and disability. Over the years treatment has not varied much-exercise, diet and use of insulin- and the problem continues to grow. If bariatric surgery shows amelioration of diabetes (if "cure" is too strong a worrd), ...
The study looks great, but I am not sure that third party payers will jump on the bandwagon and reimburse this procedure. If Medtronic can surmount this barrier it will be a fantastic growth opportunity.
This is a large and rapidly growing market, just ask the folks at Pfizer.
Excellent clinical analysis on this article has already been provided. I will focus on the marketing and sales implications. Is it more effective than Ambien? Though Ambien CR will be a generic by the time this product makes it to market, the market will have changed significantly by that time. Currently...
The STAR trial was a follow-up to the P1 trial, evaluating whether raloxifene (Evista) could be used as a preventive agent. The results were supportive of this agent in this role, and hence the FDA has approved it. There is a black box warning on stroke risk, though the results did not show a significantly...
Given the recent data on erythropoietin, this study further demonstrates the significant potential adverse events seen. Expect sales to continue to decrease, as erythropoietin drugs in the future will be used in renal failure and oncology patients to keep hematocrits in a reasonable range.
Previous data on Iressa has shown no survival benefit. This phase III trial comparing Iressa to Taxotere in locally advanced phase III NSCLC seems to show equivalence. And, clearly the Iressa was more favorable than taxotere. If the data is true, this will reignite the question...
I've previously posted on the early news of this data. We now have more information, including the response rate and median survival in this trial - and the good news is that it parallels the prior phase II data. This is promising information, but we'll still need to see the...
Financing of health care by physicians is a relatively new phenomenon. While this practice is most aggressively being used in the arena of non-covered services (plastic surgery, Lasik, etc), it has some relevance to general medicine as well. In the covered services arena, it's pretty simple...